

# 1 Organ-specific features of human kidney lymphatics are disrupted in chronic 2 transplant rejection

3  
4 Daniyal J Jafree<sup>1,2,3</sup>, Benjamin J Stewart<sup>4,5</sup>, Karen L Price<sup>1,2</sup>, Maria Kolatsi-Joannou<sup>1,2</sup>, Camille Laroche<sup>1,2</sup>, Barian Mohidin<sup>1,2</sup>, Benjamin  
5 Davis<sup>6</sup>, Hannah Mitchell<sup>7</sup>, Lauren G Russell<sup>1,2</sup>, Lucia Marinas del Rey<sup>2,8,9</sup>, Chun Jing Wang<sup>9</sup>, William J Mason<sup>1,2</sup>, Byung Il Lee<sup>10</sup>, Lauren  
6 Heptinstall<sup>2,11</sup>, Ayshwarya Subramanian<sup>12</sup>, Gideon Pomeranz<sup>1,2</sup>, Dale Moulding<sup>1</sup>, Laura Wilson<sup>1,2</sup>, Tahmina Wickenden<sup>1,2</sup>, Saif N Malik<sup>1,2</sup>,  
7 Natalie Holroyd<sup>13</sup>, Claire L Walsh<sup>13</sup>, Jennifer C Chandler<sup>1,2</sup>, Kevin X Cao<sup>1,2</sup>, Paul JD Winyard<sup>1,2</sup>, Adrian S Woolf<sup>14</sup>, Marc Aurel Busche<sup>10</sup>,  
8 Simon Walker-Samuel<sup>13</sup>, Lucy SK Walker<sup>9</sup>, Tessa Crompton<sup>15</sup>, Peter J Scambler<sup>1</sup>, Reza Motallebzadeh<sup>2,8,9</sup>, Menna R Clatworthy<sup>4,5\*</sup>,  
9 David A Long<sup>1,2\*</sup>

10  
11 <sup>1</sup>Developmental Biology & Cancer Research & Teaching Department, UCL Great Ormond Street Institute of Child Health, UCL, London, UK; <sup>2</sup>UCL  
12 Centre for Kidney & Bladder Health, UCL, London, UK; <sup>3</sup>UCL MB/PhD Programme, UCL, London, UK; <sup>4</sup>Molecular Immunity Unit, University of  
13 Cambridge, Cambridge, UK; <sup>5</sup>Wellcome Sanger Institute, Hinxton, Cambridge, UK; <sup>6</sup>Central Laser Facility, Science and Technologies Facilities  
14 Council, UK Research and Innovation, Didcot, Oxfordshire, UK; <sup>7</sup>Mathematical Sciences Research Centre, Queen's University Belfast, Belfast, UK;  
15 <sup>8</sup>Research Department of Surgical Biotechnology, Division of Surgery and Interventional Science, UCL, London, UK; <sup>9</sup>UCL Institute of Immunity  
16 and Transplantation, UCL, London, UK; <sup>10</sup>UK Dementia Research Institute at UCL, London, UK; <sup>11</sup>UCL Department of Pathology, Royal Free  
17 Hospital, London, UK; <sup>12</sup>Department of Molecular Biology and Genetics, College of Arts and Science, Cornell University, Ithaca, NY, USA; <sup>13</sup>UCL  
18 Centre for Advanced Biomedical Imaging, London, UK; <sup>14</sup>School of Biological Sciences, Faculty of Biology Medicine and Health, University of  
19 Manchester, Manchester, United Kingdom; <sup>15</sup>Infection, Immunity and Inflammation Research and Teaching Department, UCL Great Ormond Street  
20 Institute of Child Health, UCL, London, UK;

## 21 22 \*: Corresponding authors

23 Professor David A Long

24 Professor in Paediatric Nephrology & Wellcome Trust Investigator in Science,

25 Developmental Biology and Cancer Research & Teaching Department,

26 UCL Great Ormond Street Institute of Child Health

27 30 Guilford Street, London, WC1N 1EH, UK

28 Tel.: +44(0)2079052615, Email: [d.long@ucl.ac.uk](mailto:d.long@ucl.ac.uk)

29 Professor Menna R Clatworthy

30 Molecular Immunity Unit,

31 University of Cambridge Department of Medicine,

32 MRC Laboratory of Molecular Biology,

33 Cambridge Biomedical Campus,

34 Francis Crick Avenue, Cambridge. CB2 0QH, UK

35 Tel.: +44(0)1223267279, Email: [mrc38@cam.ac.uk](mailto:mrc38@cam.ac.uk)

36  
37

38

## 39 **Supplemental Materials and Methods**

40

### 41 **Sex as a biological variable**

42 Due to the exploratory nature of 3D imaging and single-cell RNA sequencing performed in this  
43 study, and the limited kidneys available for 3D imaging analysis, sex was not considered as a  
44 biological variable.

45

### 46 **Three-dimensional imaging and analysis of human kidney lymphatics**

#### 47 ***Acquisition, fixation and storage of human tissue for three-dimensional imaging***

48 Human adult kidney tissue was derived from four deceased patients who had opted in for  
49 organ donation and undergone multi-organ procurement, but for whom the kidneys had  
50 ultimately been declined for implantation by recipient transplant centres. Kidneys were  
51 retrieved by a UK National Organ Retrieval Services teams. Following *in situ* flushing of the  
52 abdominal organs with University of Wisconsin (UW) solution, the kidneys were removed and  
53 stored in UW at 4°C. Kidney allograft samples were obtained from three patients at Royal Free  
54 London NHS Trust undergoing nephrectomy for graft intolerance syndrome ( $n = 2$ ) or graft  
55 malignancy ( $n = 1$ ). All explants were performed by the transplant surgical team. Prior to  
56 acquisition, all patients were confirmed negative for COVID-19 by means of a qPCR test. After  
57 explant, pseudo-anonymised human adult kidney tissues were incubated overnight in Belzer  
58 University of Washington Cold Storage Solution (Bridge to Life Europe, London, UK) at 4°C.  
59 Prior to fixation, human adult kidney was manually dissected into ~3mm full-thickness sub-  
60 regions containing cortex and outer medulla. These tissues were then incubated in 4% (w/v)  
61 paraformaldehyde (PFA, Sigma Aldrich), made up in 1 X phosphate buffered saline (PBS), at  
62 4° C overnight. After fixation, all biological tissues were washed and stored in 1 X PBS with  
63 0.02% (w/v) sodium azide to prevent contamination. Randomly selected pieces of human adult  
64 kidney were transferred to and stored in 70% ethanol for histology.

65

**66 Wholemout immunofluorescence**

67 A modified version of the SHANEL protocol (1) was implemented for wholemount  
68 immunolabelling of kidney tissues. Unless otherwise stated, steps were performed at room  
69 temperature, and reagents purchased from Sigma Aldrich. Tissues were dehydrated in a  
70 methanol series (50, 70%) in double distilled (dd)H<sub>2</sub>O, for one hour per step, before bleaching  
71 in absolute methanol with 5% (v/v) of 30% hydrogen peroxide solution overnight at 4°C.  
72 Thereafter, tissues were rehydrated in the methanol series, followed by incubation in 1 x PBS  
73 for one hour. Overnight incubation of tissues was performed in a 0.5 M solution of acetic acid  
74 at 4°C, followed by five hours of incubation at 4°C with 4 M guanidine hydrochloride, 0.05 M  
75 sodium acetate and 2% (v/v) Triton X-100 made up in PBS. Tissues were then permeabilised  
76 with 5% (w/v) solution of 3-((3-cholamidopropyl) dimethylammonio)-1-propanesulfonate  
77 (CHAPS) made up in ddH<sub>2</sub>O overnight. Then tissues were incubated for one day in blocking  
78 solution, comprising 1 x PBS with 0.2% Triton X-100, 5% (v/v) donkey or goat serum, 5% (v/v)  
79 pooled human plasma (Biowest, Nuaille, France) and 10% (v/v) dimethyl sulfoxide (DMSO)  
80 before incubation in antibody solution (1 x PBS with 0.2% (v/v) Tween-20, 0.1% (v/v) of a  
81 10mg/ml heparin solution in ddH<sub>2</sub>O, 0.1% (w/v) saponin, 2.5% donkey or goat serum, 2.5%  
82 pooled human plasma with primary antibodies at the appropriate concentration at 4°C.  
83 Blocking and antibody solutions were further supplemented with 1:150 Human TruStain FcX™  
84 Fc Receptor Blocking Solution (BioLegend, London, UK), to reduce non-specific binding.  
85 Primary antibodies were incubated for 3-4 days, before replenishing the antibody solution and  
86 re-incubation for 3-4 days. Subsequently, tissues were washed in 1 x PBS with 0.2% Tween-  
87 20 four times for 1 hour per wash, before incubation in antibody solution with secondary  
88 antibodies at 1:200 at 4°C for four days. Tissues were then washed again in 1 x PBS with  
89 0.2% Tween-20 four times for 1 hour each and stored until dehydration and clearing.

90

**91 Primary antibodies, lectins and secondary antibodies**

92 In order of appearance in the manuscript, the following primary antibodies or lectins were used  
93 in 1.5ml incubations at the indicated concentrations: mouse anti-PDPN monoclonal (clone:

94 D2-40, 1:100, M3619, Aligent), rabbit anti-PROX1 polyclonal (1:200, ABN278, Merck), goat  
95 anti-LYVE1 polyclonal (1:100, AF2089, R&D Systems), fluorescein-conjugated LTL (1:50,  
96 Vector Laboratories), rabbit anti-UMOD monoclonal (clone: EPR20071, 1:100, ab207170,  
97 Abcam), fluorescein-conjugated UAE-I (1:50, Vector Laboratories), rabbit anti-LRP2  
98 polyclonal (1:50, ab76969, Abcam), rabbit anti-CALB1 monoclonal (clone: EP3478, 1:100,  
99 ab108404, Abcam), rhodamine-conjugated DBA (1:50, Vector Laboratories), mouse anti-  
100 CDH1 monoclonal (clone: HECD-1, 1:50, ab1416, Abcam), mouse anti-PECAM1 monoclonal  
101 (clone: JC70A, 1:50, M0823, Dako), mouse anti-CD68 monoclonal (clone: KP1, 1:100, ab955,  
102 Abcam), rabbit anti- $\alpha$ SMA polyclonal (1:50, ab5694, Abcam), rabbit anti-HLA-DR monoclonal  
103 (clone: EPR3692, 1:100, ab92511, Abcam), rabbit anti-C4d polyclonal (1:100, 0300-0230, Bio-  
104 Rad), rabbit anti-CD4 monoclonal (clone: EPR6855, 1:100, ab133616, Abcam), goat anti-  
105 CD20 polyclonal (1:100, ab194970, Abcam), goat anti-PVR polyclonal (1:100, AF2530, R&D  
106 Systems), rabbit anti-CD21 monoclonal (clone: EPR3093, 1:200, ab75985, Abcam), rat anti-  
107 PNA<sub>d</sub> monoclonal (clone: MECA-79, 1:100, MABF2050, Sigma), goat anti-CDH5 polyclonal  
108 (1:50, AF938, R&D Systems). All secondary antibodies were purchased from ThermoFisher  
109 Scientific, were conjugated to AlexaFluor fluorophores (488, 546, 568, 633 or 647) and were  
110 used at a concentration of 1:200 of the original secondary antibody stock. Controls for each  
111 panel involved omission of the primary antibody and including the secondary antibody only.

112

### 113 ***Solvent-based optical clearing***

114 Tissues were dehydrated in a methanol series (50%, 70%, 100%) for 1 hour per step. BABB  
115 (benzyl alcohol and benzyl benzoate in a 1:2 ratio), was used for clearing, with all solutions  
116 containing BABB kept in glass scintillation vials (VWR International, Lutterworth, UK). Clearing  
117 was performed in glass scintillation vials, first using BABB:methanol in a 1:1 ratio, and  
118 thereafter BABB alone, until samples equilibrated and achieved transparency.

119

120

121

**122 Confocal microscopy**

123 We took advantage of the z-depth achievable by upright confocal microscopy whilst protecting  
124 the microscope objectives. All tissues were placed between a large coverslip and cover glass,  
125 supported by a O-Ring (Polymax Ltd, Bordon, UK) made from BABB-resistant rubber, as  
126 described previously (2). Confocal images were acquired on an LSM880 upright confocal  
127 microscope (Carl Zeiss Ltd.), with a 2.5x/numerical aperture (NA) 0.085 Pan-Neofluar Dry  
128 objective (working distance; WD = 8,800  $\mu\text{m}$ ) for low-resolution imaging, and 10x/NA 0.5 W-  
129 Plan Apochromat water dipping objective (working distance; WD = 3,700  $\mu\text{m}$ ) for high-  
130 resolution imaging. Gallium arsenide phosphide (GaAsP) internal and external detectors were  
131 used for high sensitivity. To obtain higher resolution imaging, an Airyscan setting (3), consisting  
132 of a 32-channel (GaAsP) photomultiplier tube area detector.

133

**134 Lightsheet fluorescence microscopy**

135 3D imaging of cleared tissues was performed using a custom-built mesoscale selective plane  
136 illumination microscope (mesoSPIM) (4). The cleared tissue was secured in a 3D-printed  
137 holder and immersed in BABB solutions inside a quartz cuvette (40 x 40 x 100 mm).  
138 Fluorescence images were acquired with an Olympus MVX-10 macroscope at 1x  
139 magnification, resulting in a voxel size of 6.55 x 6.55 x 5  $\mu\text{m}^3$ . PDPN fluorescence signals  
140 were obtained using 638 nm laser excitation and 633nm long-pass optical filtering of emitted  
141 light, while autofluorescence was captured using 488 nm laser excitation and a 520/35 nm  
142 bandpass emission filter. Lightsheet illumination from both sides of the cuvette was carefully  
143 aligned after the sample was positioned at the centre of the macroscope's field of view and  
144 delivered simultaneously to capture a single z-stack image.

145

**146 Post-acquisition image processing**

147 All images were then exported to FIJI (NIH, Bethesda, US). Confocal image stacks were  
148 separated into individual fluorescence channels, and the Despeckle and Sharpen tools were  
149 used to reduce non-specific background fluorescence. Where maximum intensity z-

150 projections or optical z-sections were required, scale bars were applied and images and  
151 exported as TIFF files.

152

### 153 ***Image visualisation and binarization of three-dimensional imaging data***

154 Visualisation of 3D reconstructions were performed by importing confocal images to the  
155 commercial software, Imaris (v8.2, Bitplane). The Isosurface Rendering tool in Imaris allows  
156 the extraction of surfaces based on fluorescence intensity. This was used to generate  
157 segmented images fluorescence masks to visualise expression patterns, or to generate  
158 binarized outputs for extraction of vessel branching metrics. LSFM data was imported into  
159 Amira (v2020.2, Fisher Scientific) and the vasculature segmented using intensity thresholding  
160 and region growing using the Magic Wand tool to generate a binarized network.

161

### 162 ***Extraction of vessel branching metrics from three-dimensional imaging data***

163 Segmented and binarized confocal and LSFM images were imported as TIFF image stacks  
164 into Amira. The Filament Editor tool was used in Amira to generate spatial statistical  
165 parameters including vessel branch number, lengths, diameter and volumes from each  
166 segmented lymphatic plexus. The resulting values were exported these as CSV files.

167

### 168 ***Assessment of lymphatic cell-cell junctional architecture***

169 Volumes of interest of kidney tissues co-labelled with PDPN and CDH5 were segmented in  
170 IMARIS, generating a mask of PDPN signal to discriminate lymphatic-derived CDH5<sup>+</sup> signal  
171 from non-lymphatic-derived CDH5<sup>+</sup> signal, the latter corresponding to the blood vasculature.  
172 The volume of the lymphatic network from each image was determined, and the number of  
173 segmented and rendered discontinuous CDH5<sup>+</sup> structures was counted. As the lymphatic  
174 network in rejecting allografts was significantly larger, each value of discontinuous CDH5<sup>+</sup>  
175 junctions was volume normalised according to the volume of interest.

176

177

**178 Spatial statistical analysis of lymphatic-lymphocyte relationships**

179 Lymphatic 3D-skeletons were extracted from binarised confocal stacks using the BoneJ  
180 Skeletonise3d function in FIJI (5). CD4<sup>+</sup> T cell and CD20<sup>+</sup> B cell counts, centroids and areas  
181 were obtained using 3d-objectcounter with no further pre-processing (6). The mean distance  
182 of each cell from the nearest point of the lymphatic network ( $d$ ) was calculated using the cross-  
183 product 3D point-line distance:

$$184 \quad d = \frac{|(x_0 - x_1) \times (x_0 - x_2)|}{|(x_2 - x_1)|}$$

185

186 where  $x_1$  and  $x_2$  are the two closest adjacent nodes from the lymphatic 3D skeleton; found by  
187 minimizing cross-nearest neighbor distances, and  $x_0$  is the centroid of the cell of interest. To  
188 evaluate whether the cell distances were different from what would be expected by chance,  
189 within each region of interest, the CD4<sup>+</sup> T cell and CD20<sup>+</sup> B cell populations were randomly  
190 redistributed under complete spatial randomness for twenty simulations. A comparison was  
191 then made as to whether the measured mean cell-lymphatic distances fell within the 95%  
192 confidence intervals obtained through the simulations under complete spatial randomness.

193

**194 Single-cell transcriptomic analysis of human kidney lymphatics****195 Acquisition of material for single-cell transcriptomics and generation of a human  
196 kidney cell atlas**

197 The scRNA-seq dataset from this study consisted of previously published data and five new  
198 samples. For the five new samples, kidney allografts undergoing graft nephrectomies were  
199 collected at the time of surgery. Tissue was digested and processed to a single cell suspension  
200 as described previously (7). Cells were counted using a haemocytometer and cell  
201 concentrations adjusted using dilution in RPMI Medium (Sigma) to a concentration of 1000  
202 cells/ $\mu$ L. Cells were loaded according to the protocol of the 10X Chromium single cell 5'v2 kit  
203 to capture 10,000 cells per channel. Libraries were prepared according to manufacturer

204 instructions and sequencing was performed on an Illumina Novaseq instrument with read  
205 lengths specified by 10X genomics. Sequencing data were mapped against GRCh38-3.0.0  
206 using 10X Cellranger V6.0.2. These data were merged with previously published scRNA-seq  
207 data of the human kidney, including samples from non-tumorous regions of tumour  
208 nephrectomies with or without CKD (7, 8), live allograft biopsies with or without antibody-  
209 mediated rejection (9) and human kidney data from the Kidney Precision Medicine project  
210 (10). Data were merged using anndata (0.8.0), using a nuisance gene mask as previously  
211 described (7) to minimise the effect of technical noise on batch integration. Thereafter, the  
212 data were split into healthy and diseased datasets using publicly available metadata. Highly  
213 variable genes were calculated using scanpy (1.8.2) setting *n\_top\_genes* = 1500, *batch\_key*  
214 = 'dataset', and *flavour* = 'seurat\_v3' and using raw counts. On the basis of these variable  
215 genes, we constructed a variational autoencoder model using scArches (11), using both  
216 dataset and the donor identity as categorical covariate keys, and a dissociation stress score  
217 calculated from aggregate dissociation-induced gene expression (12) as a continuous  
218 covariate. A single cell variational inference (scVI) model was trained using *n\_layers* = 2, and  
219 *n\_latent* = 15. We then used the latent space computed from this model as input to scanpy's  
220 neighbourhood graph calculation and UMAP computation functions. Data were clustered  
221 using Leiden clustering and annotated on the basis of marker genes. Immune cell annotations  
222 were further supported by prediction from a logistic regression model with the CellTypist  
223 python package. The data was then converted using seurat-disk before further analysis using  
224 the Seurat package in R. Unless otherwise stated, all downstream steps were performed in  
225 Seurat.

226

### 227 ***Analysis of kidney lymphatic transcriptional heterogeneity***

228 To capture heterogeneity of lymphatic cells within the human kidney, the cell cluster  
229 corresponding to lymphatics was extracted from the control kidney dataset, and a raw count  
230 matrix was generated from all 295 lymphatic cells. We combined this with data from a recent  
231 study utilising scRNA-seq to examine nine human control kidneys after tumour nephrectomies



232 (13). From the latter dataset, a cluster of 157 lymphatic cells was identified and the raw count  
233 matrix merged with our dataset, giving a total of 452 lymphatic cells. A subset of newly  
234 generated count matrix was created to only include genes detected in both datasets, resulting  
235 in 15,316 genes. The data was pre-processed using the Seurat workflow including  
236 normalisation, scaling by all genes and principal component (PC) analysis. Integration of the  
237 two lymphatic cell datasets was achieved using the Harmony package, integrating by the study  
238 from which the cells were sourced. The *FindNeighbors*, *FindClusters* and *RunUMAP*  
239 algorithms were then computed, using 7 PCs, a resolution of 0.4 and utilising the embeddings  
240 generated by Harmony integration. Differential expression analysis was performed as below  
241 to discriminate subcluster-specific markers from the two transcriptionally distinct clusters  
242 detected.

243

#### 244 **Creation of a human organ lymphatic atlas**

245 Count matrices of publically available datasets from the Human Cell Atlas, including skin (14),  
246 breast (15), heart (16, 17), lung (18) and small or large intestines (19), were downloaded.  
247 Lymphatic endothelium was identified and isolated from the metadata of each dataset and  
248 individually curated for the expression of *PROX1* and *PDPN*. We generated a count matrix  
249 which included each of these datasets, and the 452 lymphatic cells from control kidneys  
250 computationally isolated as aforementioned. Genes that not detected across all datasets or  
251 that were not represented in all count matrices were deleted to avoid artefactual clustering.  
252 The analysis workflow described as above, including Harmony integration, was then used,  
253 performing integration by individual donor. Predicted transcription factor activity was assessed  
254 using the SCENIC package in R.

255

#### 256 **Assessment of kidney lymphatic-enriched candidates in human kidney diseases**

257 To assess the expression of *DNASE1L3* and *MDK* across a range of human kidney diseases,  
258 the NephroSeq database was used. We searched for RNAseq or microarray expression  
259 datasets containing these transcripts, only including datasets that assessed tubulointerstitial

260 gene expression. The datasets were compiled and  $\log_2$  expression values were extracted and  
261 plotting using Violin plots.

262

### 263 **Differential expression analysis**

264 The *FindAllMarkers* function was used for differential expression analysis of scRNAseq data.  
265 Wilcoxon Rank Sum tests were used to assess statistically significant (adjusted  $p$  value  $\leq$   
266 0.05) between average log fold change values of expression. Selected differentially expressed  
267 genes were visually represented using the *VlnPlot* function, the *DoHeatMap* function or using  
268 the EnhancedVolcano (<https://github.com/kevinblighe/EnhancedVolcano>) package. For  
269 NephroSeq data,  $\log_2$  expression values were assessed using ANOVA tests with Tukey post-  
270 hoc correction for individual comparisons.

271

### 272 **Gene ontology analysis**

273 Gene ontology (GO) analysis was performed using the PANTHER tool for gene classification.  
274 Lists of differentially expressed genes, were exported and input into the PANTHER web tool  
275 (v16.0, <http://www.pantherdb.org>), using statistical overrepresentation tests to group genes  
276 using the GO biological processes complete database. Fisher's Exact tests were used to  
277 assess for statistical enrichment of genes for selected GO terms, and a false discovery rate  
278 (FDR)  $p \leq 0.05$  was considered significant.

279

### 280 **CellPhoneDB**

281 To infer putative cell-cell interactions in single-cell RNA sequencing data, the CellPhoneDB  
282 resource (20) was used. Using normalised count and metadata files obtained from Seurat,  
283 CellPhoneDB was called by running appropriate commands, obtained from  
284 <https://github.com/Teichlab/cellphonedb>, in the command line through a Python virtual  
285 environment. The *statistical\_analysis* method was used to assess predicted interactions,  
286 before functions in ktPlots (<https://github.com/zktuong/ktplots>) were used to generate custom  
287 dot plots or circle plots.

**288 Lymphatic endothelial cell stimulation assays****289 Cell line and recombinant IFN $\gamma$  treatment**

290 Adult human dermal lymphatic endothelial cells (HDLECs; PromoCell GmbH) were cultured  
291 in Endothelial Cell Growth Medium MV2 (PromoCell) at 37 °C in a 5% CO<sub>2</sub> incubator. Media  
292 were refreshed twice weekly, and confluent cultures were passaged at a 1:3 ratio. cells ( $n = 2$   
293 independent lines) were seeded at a density of  $1 \times 10^5$  in a 6-well plate, treated with either  
294 normal growth media (unstimulated group) or IFN $\gamma$  (50ng/ml; Thermo Fisher Scientific,) for 24  
295 hours, 48 hours and 72 hours.

296

**297 Quantitative RT-PCR for LGALS9 expression by HDLECs**

298 To assess *LGALS9* RNA expression, cells at each time point were harvested, lysed and total  
299 RNA extracted using the RNeasy Plus Mini Kit (Qiagen). cDNA was synthesised from 500 ng  
300 RNA using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories). Quantitative real-time PCR  
301 was performed on a CFX96 Real-Time PCR System (Bio-Rad) using qPCRBIO SyGreen Mix  
302 Lo-ROX (PCR Biosystems Ltd). Expression of *LGALS9* was normalised to the housekeeping  
303 gene *HPRT*, and fold-change was calculated using the  $2^{-\Delta\Delta CT}$  method. Results were  
304 standardised to the mean expression in untreated controls (set to 1). The experiment was  
305 repeated three times and all assays performed in duplicate. The presented data shows the  
306 mean fold-change in gene expression measured in three independent cell lines. Primer  
307 sequences are available upon request.

308

**309 Assessment and quantification of LGALS9 secretion by HDLECs**

310 To assess *LGALS9* protein secretion, conditioned media from HDLECs at each timepoint were  
311 collected and centrifuged to remove cell debris. Galectin-9 levels were quantified by ELISA

312 (DGAL90, R&D Systems) according to the manufacturer's instructions. Optical density was  
313 measured at 450 nm, and protein concentration was calculated using a standard curve derived  
314 from serial dilutions of recombinant LGALS9. The experiment was repeated three times and  
315 all assays performed in duplicate. Results were expressed relative to unstimulated wells,  
316 which were standardised to a value of 1.

317

## 318 **Statistical analysis, data presentation and availability**

### 319 ***Sample size estimation***

320 In prior work examining the 3D architecture of lymphatic vessels in lymphangiomatous skin  
321 biopsies, conclusions were drawn based on the evaluation of three samples within the control  
322 group (21), and so a minimum of three patients per group were used to draw conclusions.  
323 For scRNA-seq, the number of samples and cells to be analysed was limited by the size of  
324 the dataset. The specific number of replicates used for each experiment and the number of  
325 regions images are indicated in the figure legends,

326

### 327 ***Reproducibility and data presentation***

328 Descriptive conclusions are drawn based on a minimum of four imaging volumes of interest,  
329 each taken from samples from at least two different human kidneys. All confocal and brightfield  
330 images were exported and saved as TIFF files. Where brightness or contrast were adjusted,  
331 this was applied uniformly across all conditions within the same figure, and details are stated  
332 in figure legends. Cell culture experiments were performed in biological triplicates, with a  
333 minimum of two technical replicates for each assay. Graphs were generated in GraphPad  
334 PRISM and saved as TIFF format. Visualisations from scRNA-seq analysis were performed in  
335 RStudio and PNG screenshots were taken and saved. Figures were compiled in Microsoft  
336 PowerPoint (Microsoft, Redmond, US) and saved as PDF format.

337

338

339 **Statistics**

340 Except for scRNA-seq analysis and lymphatic-lymphocyte spatial relationships, all remaining  
341 statistical comparisons were performed using GraphPad PRISM. A two-tailed  $p$  value of less  
342 than 0.05 was considered statistically significant. For continuous data, Shapiro-Wilk tests were  
343 used to assess normality of distribution and Brown-Forsythe tests were used equality of  
344 variance. Where normal distribution and equality of variances were satisfied, data is presented  
345 as mean  $\pm$  standard deviation. When graphed, error bars were used to represent the standard  
346 error of the mean. Student's  $t$ -test was used to compare two groups and ANOVA was used to  
347 compare more than two groups, applying post-hoc Bonferroni tests to provide adjusted  $p$   
348 values for multiple comparisons. Statistics for scRNA-seq analysis were performed in RStudio  
349 and are as detailed above.

350

351 **Study approval**

352 For reference human kidney tissue, consent for the use of the organs for research was  
353 obtained from the donor family by Specialist Nurses in Organ Donation before organ retrieval  
354 and were then offered for research by NHS Blood & Transplant (NHSBT) if they were found  
355 to be unsuitable for transplantation by the surgical team. Ethical approval was granted by the  
356 National Research Ethics Committee in the UK (21/WA/0388) and was approved by The Royal  
357 Free London NHS Foundation Trust-UCL Biobank Ethical Review Committee (RFL B-ERC;  
358 NC.2018.010; IRAS 208955). Ethical approval to obtain explants with chronic rejection was  
359 covered by a prior agreement (NC.2018.007, UCL Biobank Ethical Review Committee, Royal  
360 Free London NHS Foundation Trust, B-ERC-RF). Human kidney tissues for scRNA-seq were  
361 explanted and processed at Cambridge University Hospitals NHS Foundation Trust under  
362 ethical approval (REC 16/EE/0014). Ethical approval for publicly available data for human  
363 lymphatic cells acquired from scRNA-seq experiments of kidney (22), skin (14), breast (15),  
364 heart (16, 17), lung (18) and intestines (19) are detailed in the original studies.

365

366

367 **Data availability**

368 Raw sequencing data for the five new human kidney scRNAseq samples have been made  
369 publicly accessible via the European Genome-phenome Archive (Accession number:  
370 EGAD00001015631). The annotated and processed Seurat objects and h5ad files are publicly  
371 available: <https://doi.org/10.5281/zenodo.7566982>. The code for analysis of the human kidney  
372 scRNA-seq atlas is available at <https://github.com/daniyal-jafree1995/>. The imaging data used  
373 is available from the lead contact upon request. All raw data used to plot graphs, except for  
374 scRNA-seq analyses, are provided within the Supporting Data Values document.

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

## 395 REFERENCES

- 396  
397 1. Zhao S et al. Cellular and molecular probing of intact human organs.. *Cell* 2020;180(4):796–  
398 812.e19.
- 399 2. Jafree DJ, Long DA, Scambler PJ, Moulding D. Tissue Clearing and Deep Imaging of the Kidney  
400 Using Confocal and Two-Photon Microscopy.. *Methods Mol. Biol.* 2020;2067:103–126.
- 401 3. Huff J. The Airyscan detector from ZEISS: confocal imaging with improved signal-to-noise ratio and  
402 super-resolution. *Nat. Methods* 2015;12(12):i–ii.
- 403 4. Voigt FF et al. The mesoSPIM initiative: open-source light-sheet microscopes for imaging cleared  
404 tissue.. *Nat. Methods* 2019;16(11):1105–1108.
- 405 5. Lee TC, Kashyap RL, Chu CN. Building Skeleton Models via 3-D Medial Surface Axis Thinning  
406 Algorithms. *CVGIP: Graphical Models and Image Processing* 1994;56(6):462–478.
- 407 6. Bolte S, Cordelières FP. A guided tour into subcellular colocalization analysis in light microscopy..  
408 *J. Microsc.* 2006;224(Pt 3):213–232.
- 409 7. Stewart BJ et al. Spatiotemporal immune zonation of the human kidney.. *Science*  
410 2019;365(6460):1461–1466.
- 411 8. Kuppe C et al. Decoding myofibroblast origins in human kidney fibrosis.. *Nature*  
412 2021;589(7841):281–286.
- 413 9. Malone AF et al. Harnessing expressed single nucleotide variation and single cell RNA sequencing  
414 to define immune cell chimerism in the rejecting kidney transplant.. *J. Am. Soc. Nephrol.*  
415 2020;31(9):1977–1986.
- 416 10. Menon R et al. Single cell transcriptomics identifies focal segmental glomerulosclerosis remission  
417 endothelial biomarker.. *JCI Insight* 2020;5(6). doi:10.1172/jci.insight.133267
- 418 11. Lotfollahi M et al. Mapping single-cell data to reference atlases by transfer learning.. *Nat.*  
419 *Biotechnol.* 2022;40(1):121–130.
- 420 12. van den Brink SC et al. Single-cell sequencing reveals dissociation-induced gene expression in  
421 tissue subpopulations.. *Nat. Methods* 2017;14(10):935–936.
- 422 13. Subramanian A et al. Obesity-instructed *TREM2* macrophages identified by  
423 comparative analysis of diabetic mouse and human kidney at single cell resolution. *BioRxiv* [published  
424 online ahead of print: May 30, 2021]; doi:10.1101/2021.05.30.446342
- 425 14. Reynolds G et al. Developmental cell programs are co-opted in inflammatory skin disease..  
426 *Science* 2021;371(6527). doi:10.1126/science.aba6500
- 427 15. Kumar T et al. A spatially resolved single-cell genomic atlas of the adult human breast.. *Nature*  
428 2023;620(7972):181–191.
- 429 16. Kanemaru K et al. Spatially resolved multiomics of human cardiac niches.. *Nature*  
430 2023;619(7971):801–810.
- 431 17. Litviňuková M et al. Cells of the adult human heart.. *Nature* 2020;588(7838):466–472.
- 432 18. Sikkema L et al. An integrated cell atlas of the lung in health and disease.. *Nat. Med.*  
433 2023;29(6):1563–1577.
- 434 19. Elmentaite R et al. Cells of the human intestinal tract mapped across space and time.. *Nature*  
435 2021;597(7875):250–255.
- 436 20. Efremova M, Vento-Tormo M, Teichmann SA, Vento-Tormo R. CellPhoneDB: inferring cell-cell  
437 communication from combined expression of multi-subunit ligand-receptor complexes.. *Nat. Protoc.*  
438 2020;15(4):1484–1506.
- 439 21. Hägerling R et al. VIPAR, a quantitative approach to 3D histopathology applied to lymphatic  
440 malformations.. *JCI Insight* 2017;2(16). doi:10.1172/jci.insight.93424
- 441 22. Subramanian A et al. Obesity-instructed *TREM2* macrophages identified by  
442 comparative analysis of diabetic mouse and human kidney at single cell resolution. *BioRxiv* [published  
443 online ahead of print: May 30, 2021]; doi:10.1101/2021.05.30.446342
- 444